Kimberly’s Story

Site created on September 29, 2023

Welcome to our CaringBridge website. We are using it to keep family and friends updated in one place. We appreciate your support and words of hope and encouragement. Thank you for visiting.  

I was diagnosed with clear cell endometrial cancer on August 31, 2023.  After surgery on Sept 21, 2023 pathology found 2 rare and aggressive cancers.   Mixed clear cell and serous cell endometrial cancer with metastases to the outside of the ovaries and beyond.  The gynecological oncologist is a wonderful and knowledgeable person at MD Anderson in Jacksonville, FL.

Newest Update

Journal entry by

(7) Facebook

Please join me on my facebook page link above or the following youtube page (3) Rare and aggressive. Clear cell endometrial cancer, serous cell endometrial cancer. - YouTube

I am doing quite well with chemotherapy and immunotherapy.  There is no news of imminent demise or me going downhill quickly so the caring bridge platform is not what I want to continue at this time.  I feel great and my family and friends are very supportive.  The church family is wonderful, and life is good!  My mother's friends are supportive.  Plus, I look really cute bald!

So here is the plan.  I have a 30 to 50% chance of lasting 5 years up from 15 to 20%.  My chances might be higher because of Keytruda (immunotherapy)...they really don't know about that factor.  I have chemo every 21 days unless my blood count is too low in certain areas.  For example, this chemo, my platelets were too low and I have to wait a week.  Six treatments of chemo and then 6 weeks of radiation.   

Thank you all!

Patients and caregivers love hearing from you; add a comment to show your support.
Help Kimberly Stay Connected to Family and Friends

A $25 donation to CaringBridge powers a site like Kimberly's for two weeks. Will you make a gift to help ensure that this site stays online for them and for you?

Comments Hide comments

Show Your Support

See the Ways to Help page to get even more involved.

SVG_Icons_Back_To_Top
Top